NCT00843882 2026-03-18
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
35 trialsNCT03901963 2026-03-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT00602641 2026-03-03
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT01169337 2025-11-25
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT01476787 2025-05-14
RELEVANCE
Celgene
Phase 3 Completed
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03859427 2024-08-13
ARROW2
Amgen
Phase 3 Completed
NCT02285062 2023-06-22
ROBUST
Celgene
Phase 3 Completed
NCT02516696 2023-06-05
BiRd vs Rd
Weill Medical College of Cornell University
Phase 3 Terminated
NCT01564537 2023-03-10
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 3 Completed
NCT01938001 2023-02-22
AUGMENT
Celgene
Phase 3 Completed
NCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00774345 2021-12-02
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Celgene
Phase 3 Completed
NCT02322320 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00622336 2019-11-20
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00928486 2019-11-20
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Celgene
Phase 3 Completed
NCT01021423 2019-11-19
RENEW
Celgene
Phase 3 Terminated
NCT00910910 2019-07-09
ORIGIN
Celgene
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT00988208 2018-04-04
Mainsail
Celgene
Phase 3 Completed
NCT01621672 2015-10-19
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
University of Arkansas
Phase 3 Completed
NCT00522392 2015-06-26
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00064038 2015-03-25
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT00420849 2012-05-21
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00478777 2011-11-03
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00179647 2010-03-16
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed